1. Inhibition of VEGF-Induced VEGFR-2 Activation and HUVEC Migration by Melatonin and Other Bioactive Indolic Compounds
   Ana Cerezo et al, 2017, Nutrients CrossRef
2. Melatonin, a novel selective ATF-6 inhibitor, induces human hepatoma cell apoptosis through COX-2 downregulation
   Li-Jia Bu et al, 2017, WJG CrossRef
3. Melatonin and Hippo Pathway: Is There Existing Cross-Talk?
   Federica Lo Sardo et al, 2017, IJMS CrossRef
4. Melatonin and Cancer Hallmarks
   Wamidh Talib, 2018, Molecules CrossRef
5. Idiopathic pulmonary fibrosis (IPF) signaling pathways and protective roles of melatonin
   Azam Hosseinzadeh et al, 2018, Life Sciences CrossRef
6. Human hepatocellular carcinoma: Protection by melatonin
   Keywan Mortezaee, 2018, J Cell Physiol CrossRef
7. 3D MR Elastography of Hepatocellular Carcinomas as a Potential Biomarker for Predicting Tumor Recurrence
   Jin Wang et al, 2018, J. Magn. Reson. Imaging CrossRef
8. Melatonin and its anti-glioma functions: a comprehensive review
   Sayantan Maitra et al, 2019 CrossRef
9. Melatonin: An important anticancer agent in colorectal cancer
   Mohammad Mirza‐Aghazadeh‐Attari et al, 2019, J Cell Physiol CrossRef
10. Melatonin Enhances the Usefulness of Ionizing Radiation: Involving the Regulation of Different Steps of the Angiogenic Process
    Alicia González-González et al, 2019, Front. Physiol. CrossRef
11. Melatonin as an anti-inflammatory agent in radiotherapy
    M. Najafi et al, 2017, Inflammopharmacol CrossRef
12. Aberrant cancer metabolism in epithelial–mesenchymal transition and cancer metastasis: Mechanisms in cancer progression
    Run Huang et al, 2017, Critical Reviews in Oncology/Hematology CrossRef
13. Melatonin as a promising agent to treat ovarian cancer: molecular mechanisms
    Luiz Gustavo de Almeida Chuffa et al, 2017 CrossRef
14. Melatonin as an angiogenesis inhibitor to combat cancer: Mechanistic evidence
    Nasser Hashemi Goradel et al, 2017, Toxicology and Applied Pharmacology CrossRef
15. Ketogenic Diet Combined With Melatonin Overcomes Cisplatin and Vincrisitne Drug Resistance in Breast Carcinoma Syngraft
    Wamidh H. Talib, 2019, Nutrition CrossRef
16. Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process
    Alicia González-González et al, 2020, Sci Rep CrossRef
17. Melatonin: An atypical hormone with major functions in the regulation of angiogenesis.
    Mohammad Mirza-Aghazadeh-Attari et al, 2020, IUBMB Life CrossRef
18. Down regulation of RNA binding motif, single-stranded interacting protein 3, along with up regulation of nuclear HIF1A correlates with poor prognosis in patients with gastric cancer
    Youliang Wu et al, 2017, Oncotarget CrossRef
19. Melatonin as a potential inhibitory agent in head and neck cancer
    Chia-Ming Yeh et al, 2017, Oncotarget CrossRef
20. Melatonin Antagonizes Nickel-Induced Aerobic Glycolysis by Blocking ROS-Mediated HIF-1α/miR210/ISCU Axis Activation
    Mindi He et al, 2020, Oxidative Medicine and Cellular Longevity CrossRef
21. Melatonin regulates the expression of inflammatory cytokines, VEGF and apoptosis in diabetic retinopathy in rats
    Ismaela Maria Ferreira de Melo et al, 2020, Chemico-Biological Interactions CrossRef
22. Melatonin: an endogenous miraculous indolamine, fights against cancer progression
    Saptadip Samanta, 2020, J Cancer Res Clin Oncol CrossRef
23. Hypoxia, metabolism, and the circadian clock: new links to overcome radiation resistance in high-grade gliomas
    Han Shen et al, 2020, J Exp Clin Cancer Res CrossRef
24. Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF-1α/ROS/VEGF
    Jiao Cheng et al, 2018, Int J Mol Med CrossRef
25. Transcriptomic analysis on the effects of melatonin in gastrointestinal carcinomas
    Lu Ao et al, 2020, BMC Gastroenterol CrossRef
26. Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration.
    Carmen Rodriguez, 0 CrossRef
27. Melatonin and gastrointestinal cancers: Current evidence based on underlying signaling pathways
    Mohammad Hossein Pourhanifeh et al, 2020, European Journal of Pharmacology CrossRef
28. Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes.
    Parisa Maleki Dana et al, 2020, IUBMB Life CrossRef
29. Two neuroendocrine G protein‐coupled receptor molecules, somatostatin and melatonin: Physiology of signal transduction and therapeutic perspectives
    Eva Costanzi et al, 2020, J Cell Physiol CrossRef
30. Therapeutic targets of cancer drugs: Modulation by melatonin
    Milad Moloudizargari et al, 2020, Life Sciences CrossRef
31. Melatonin Lowers HIF-1α Content in Human Proximal Tubular Cells (HK-2) Due to Preventing Its Deacetylation by Sirtuin 1
    Aleksandra Owczarek et al, 2021, Front. Physiol. CrossRef
32. Melatonin as an Antitumor Agent against Liver Cancer: An Updated Systematic Review
    Paula Fernández-Palanca et al, 2021, Antioxidants CrossRef
33. Role and Therapeutic Potential of Melatonin in Various Type of Cancers
    Sangiliyandi Gurunathan et al, 2021, OTT CrossRef
34. Melatonin and its mechanism of action in the female reproductive system and related malignancies
    Maryam Ezzati et al, 2021, Mol Cell Biochem CrossRef
35. Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
    Wamidh H. Talib et al, 2021, Molecules CrossRef
36. Metabolic Anti-Cancer Effects of Melatonin: Clinically Relevant Prospects
    Marek Samec et al, 2021, Cancers CrossRef
37. Modulation of the tumor microenvironment (TME) by melatonin
    Qi Mu et al, 2021, European Journal of Pharmacology CrossRef
38. Melatonin is a potential oncostatic agent to inhibit HepG2 cell proliferation through multiple pathways
    Omar A. Ammar et al, 2022, Heliyon CrossRef
39. Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy
    Niloufar Targhazeh et al, 2022, Biochimie CrossRef
40. Molecular basis of melatonin protective effects in metastasis: A novel target of melatonin
    Fatemeh Sadoughi et al, 2022, Biochimie CrossRef
41. Effectiveness and Safety of Combination Therapy of Transarterial Chemoembolization and Apatinib for Unresectable Hepatocellular Carcinoma in the Chinese Population: A Meta-Analysis.
    Yan Wei et al, 2019, Chemotherapy CrossRef
42. Oncostatic activities of melatonin: Roles in cell cycle, apoptosis, and autophagy
    Niloufar Targhazeh et al, 2022, Biochimie CrossRef
43. Melatonin as an oncostatic agent: Review of the modulation of tumor microenvironment and overcoming multidrug resistance
    Niloufar Targhazeh et al, 2022, Biochimie CrossRef
44. Melatonin inhibits HCC progression through regulating the alternative splicing of NEMO
    Lu Bai et al, 2022, Front. Pharmacol. CrossRef
45. Comparing the Effectiveness and Safety of Sorafenib Plus TACE with Apatinib Plus Tace for Treating Patients with Unresectable Hepatocellular Carcinoma: A Multicentre Propensity Score Matching Study
    Kai-Cai Liu et al, 2021, SSRN Journal CrossRef
46. Anti-proliferative effect of melatonin in human hepatoma HepG2 cells occurs mainly through cell cycle arrest and inflammation inhibition
    Heba K. Nabih et al, 2023, Sci Rep CrossRef
47. Fucoidan/chitosan layered PLGA nanoparticles with melatonin loading for inducing intestinal absorption and addressing triple-negative breast cancer progression
    Yu-Wei Yen et al, 2023, International Journal of Biological Macromolecules CrossRef
48. The Relationship Between Melatonin 1-2 Receptor Expression in Patients With Epithelial Ovarian Cancer and Survival
    Elifnur Bicer et al, 2023 CrossRef
49. null
    Nithar Ranjan Madhu et al, 2024 CrossRef
50. Prognostic Evaluation for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Patients Treated with Transarterial Chemoembolization Plus Molecular Targeted Therapies—Development and Validation of the ABPS Score
    Kaicai Liu et al, 2024, Academic Radiology CrossRef
51. null
    Emma Sola et al, 2024 CrossRef